Atypical fibroxanthoma: DNA ploidy analysis of 14 cases with possible histogenetic implications

Worrell, JC; Ansari, M. Qasim; Ansari, S. J.; Cockerell, Clay J.

doi:10.1111/j.1600-0560.1993.tb00645.x

Cited by 33 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence to support them being different entities includes differential expression of H and K ras, 18 MIB1, 19 CD74, 20 and ploidy differences. 19,21 Similarities have also been claimed, with comparable AgNOR numbers, 22 p53 and bcl2 expressions, and apoptotic and proliferation markers. 23 This report represents the largest series of AFX reported in the literature to date.…”

Section: Discussionmentioning

confidence: 67%

Atypical Fibroxanthoma: A Histological and Immunohistochemical Review of 171 Cases

Beer¹,

Drury²,

Heenan³

2010

The American Journal of Dermatopathology

122

140

View full text Add to dashboard Cite

The clinical and histological features of 171 atypical fibroxanthomas (AFX) from a single institution in Western Australia are outlined. This area experiences high levels of solar radiation, and all assessable biopsies showed solar elastosis. Patients were aged between 41 and 97 years (median age 74), with 76% of tumors occurring in men (male to female ratio approximately 3 to 1). Most tumors were small, with a median diameter of 10 mm and a range of 4-35 mm. Only 5% exceeded 20 mm in diameter. Most AFX were well-circumscribed dermal lesions, with limited invasion of subcutis in a minority. Histological variants identified included keloidal (n = 8), clear cell (n = 3), and granular cell (n = 3), plaque like (n = 4), and myxoid (n = 1). Bland cytological appearances (spindle cell nonpleomorphic AFX) were noted in 5 tumors, with osteoclast-like giant cells in 2. Features suggesting regression were present in 22 cases. Two cases recurred locally, none metastasized. No tumors expressed melanocytic or epithelial markers. Seventy-four percent of cases expressed smooth muscle actin, typically strongly and diffusely. No AFX stained with desmin. Only 1 of 50 cases was CD117 positive. In conclusion, AFX may show a wide range of histological appearances, and a panel of immunohistochemical markers is essential to make the correct diagnosis. Histological mimics, such as poorly differentiated squamous cell carcinoma, must be carefully excluded. Specific diagnosis is important because there seems to be a very low risk of recurrence or metastasis despite the frequently alarming histology.

show abstract

Section: Discussionmentioning

confidence: 67%

Atypical Fibroxanthoma: A Histological and Immunohistochemical Review of 171 Cases

Beer¹,

Drury²,

Heenan³

2010

The American Journal of Dermatopathology

122

140

View full text Add to dashboard Cite

show abstract

“…11 In addition, diploidy has been observed in AFX, in contrast to MFH in which the majority of chromosomal changes were aneuploid. 12 Atypical fibroxanthoma and MFH have been differentiated on the basis of CD74/LN-2 positivity in one report. 2 Reduced immunoexpression for CD74/LN-2 in AFX distinguishes it from MFH.…”

Section: Discussionmentioning

confidence: 97%

Superficial malignant fibrous histiocytoma presenting as recurrent atypical fibroxanthoma

Ly¹,

Selva

James

et al. 2004

Aust J Dermatology

View full text Add to dashboard Cite

Atypical fibroxanthoma (AFX) and malignant fibrous histiocytoma (MFH) are neoplasms of probable fibrohistiocytic lineage. The precise relationship between AFX and MFH remains controversial. We present two cases in which a lesion was excised from the face of an elderly person and reported as AFX. Both cases recurred within 12 months and were reclassified as MFH. They were excised with slow Mohs' micrographic surgery, with adjuvant radiotherapy in one case. In the other, a further recurrence was treated with orbital exenteration and radiotherapy. We review the difficulties in differentiating between AFX and MFH and the implications for treatment.

show abstract

“…Sixteen cases were found, and the diagnosis was confirmed by a single board-certified dermatopathologist (MBM). These diagnoses were rendered on the basis of published morphologic criteria and with the aid of immunohistochemical markers typically CD68 (+), S100 (2), smooth muscle actin (2), cytokeratin 903 (2), and pankeratin (2). Inclusion criteria also included adequate blocked tissue for IHC study and for obtaining demographic data.…”

Section: Methodsmentioning

confidence: 99%

CD117 Immunoreactivity in Atypical Fibroxanthoma

Mathew

Schlauder²,

Calder³

et al. 2008

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Atypical fibroxanthoma (AFX) is a spindle cell neoplasm of the skin seen typically on sun-damaged skin of the elderly. Though described as a benign entity, local recurrence and distant metastasis have been reported. This study aims to investigate the potential pathogenic role of CD117, the c-kit receptor in AFX. CD117 was detected in 15 of the 16 cases (94%). The percentage of positive cells for CD117 expression among all tumors was approximately 30%. CD117 proved to be a very sensitive marker of AFX. This antibody may be a useful diagnostic adjunct in AFX.

show abstract

Atypical fibroxanthoma: DNA ploidy analysis of 14 cases with possible histogenetic implications

Cited by 33 publications

References 17 publications

Atypical Fibroxanthoma: A Histological and Immunohistochemical Review of 171 Cases

Atypical Fibroxanthoma: A Histological and Immunohistochemical Review of 171 Cases

Superficial malignant fibrous histiocytoma presenting as recurrent atypical fibroxanthoma

CD117 Immunoreactivity in Atypical Fibroxanthoma

Contact Info

Product

Resources

About